RxDoctor Payments Data

Jorge Martinez, MD

Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1396798492

Payments from drug & device makers

$911in general payments, 2019–2025

Across 38 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer Puerto Rico Inc.$273
  • Merck$138
  • AstraZeneca$121
  • Dexcom, Inc.$100
  • Boston Scientific$88
  • Mentor Worldwide LLC$67
  • plus $125 from 4 others

What the payments were for

  • Food & beverage$911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer Puerto Rico Inc.12$273
Merck7$138
AstraZeneca6$121
Dexcom, Inc.5$100
Boston Scientific1$88
Mentor Worldwide LLC1$67
Abbott2$47
AbbVie2$43
Sanofi-aventis U.S. LLC1$20
Bayer1$15

How this compares

$911 in reported general payments places this provider in the 15th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,998
Medicare patients
41
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trijardy XrEmpaglifloz/Linaglip/Metformin373$446,435
FarxigaDapagliflozin Propanediol188$238,825
Janumet XrSitagliptin Phos/Metformin Hcl223$238,735
SynthroidLevothyroxine Sodium2,147$231,605
JanuviaSitagliptin Phosphate98$121,162
GlyxambiEmpagliflozin/Linagliptin99$106,222
OzempicSemaglutide91$100,613
TrulicityDulaglutide79$97,875
JardianceEmpagliflozin66$94,330
LantusInsulin Glargine,hum.Rec.Anlog518$53,313
Synjardy XrEmpagliflozin/Metformin Hcl42$44,291
HumalogInsulin Lispro397$44,213
EliquisApixaban20$32,837
Jentadueto XrLinagliptin/Metformin Hcl38$31,336
Humalog Mix 75-25Insulin Lispro Protamin/Lispro139$31,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet Xr, Januvia, Janumet$138$375,091341 claims
AstraZenecaFarxiga$121$238,825188 claims
AbbVieSynthroid$43$231,6052,147 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$20$65,801531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →